Naadira Vanker

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial”.

High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial

American Journal of Respiratory and Critical Care Medicine(2024)10.1164/rccm.202311-2004oc

N/A

0.741DataRank · unranked

13 citations

Elisa H. Ignatius, Veronique de Jager, Caryn M. Upton, Soyeon Kim, Ashley McKhann +14 more

Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis

Science Translational Medicine(2021)10.1126/scitranslmed.abd7618

N/A

0DataRank · unranked

47 citations

Veronique de Jager, Ray Y. Chen, Lori E. Dodd, Praveen Paripati, Laura E. Via +19 more

The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis

Frontiers in Pharmacology(2021)10.3389/fphar.2021.637618

N/A

0DataRank · unranked

4 citations

Veronique de Jager, Elana van Brakel, Helmuth Reuter, Nikhil Gupte, Naadira Vanker +7 more